NSE: ALKEM | BSE: 539523

Mid-range Performer

Download real time

5166.00 -35.00 (-0.67%)

Near 52W Low of ₹5051.00

28,026 NSE+BSE Volume

NSE 15 Oct, 2026 12:31 PM (IST)

61,767.3

Market Cap

High in industry

Beta 1Year

Very Low volatility

Alkem Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ALKEM, BSE:539523 Alkem Laboratories Ltd.

Search Inside the pdf :

Alkem Laboratories Ltd.

15 Aug 2026, 12:00AM

5166.00

-0.67%

Strong margin-led beat

Neutral: Alkem Laboratories Ltd.

Target

Motilal Oswal

ALKEM delivered in-line revenue and EBITDA/PAT beat of 16%/19% in 1QFY27, driven by improved segmental mix and higher-than-expected operating leverage.

Alkem Laboratories L.. has an average target of 5736.67 from 3 brokers.

Alkem Laboratories Ltd.

14 Aug 2026, 12:00AM

5166.00

-0.67%

Alkem Labs (SELL): US sales challenging; tax rate rising; valuations expensiveSales/EBITDA/PAT were 0.8%/5.9%/-0.3% above our estimates. EBITDA margin surpassed our estimate by 98 bps to 19.5%View Report

Sell: Alkem Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT were 0.8%/5.9%/-0.3% above our estimates. EBITDA margin surpassed our estimate by 98 bps to 19.5%

Alkem Laboratories Ltd.'s price crossed below 30Day SMA today

Alkem Laboratories Ltd.

29 May 2026

5166.00

-0.67%

Alkem Labs (SELL): EBITDA Margin likely flat in FY27; valuations expensive

Sell: Alkem Laboratories Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Sales/EBITDA/APAT reported 4.8%/7.4%/-4.4% above our estimates. EBITDA Margin reported 36 bps above our estimates at 14.4%

Alkem Laboratories Ltd. is trading below all available SMAs

Alkem Laboratories Ltd.

28 May 2026

5166.00

-0.67%

Resilient growth in India; robust FY27 outlook

Buy: Alkem Laboratories Ltd.

Target

ICICI Securities Limited

Alkem Laboratories (Alkem)’s Q4FY26 performance was decent. India branded grew 10% while reported growth of India business was lower at 8.9% due to restructuring of trade generics.

Alkem Laboratories L.. has an average target of 5736.67 from 3 brokers.

Alkem Laboratories Ltd.

28 May 2026

5166.00

-0.67%

Strong finish; softer road ahead

Neutral: Alkem Laboratories Ltd.

Target

Motilal Oswal

Alkem Laboratories (ALKEM) delivered a better-than-expected financial performance with a 4%, 6%, and 16% beat on revenue, EBITDA, and PAT for 4QFY26.

Alkem Laboratories Ltd. is trading below all available SMAs

Alkem Laboratories Ltd.

18 Feb 2026

5166.00

-0.67%

Expanding scope of business in the Medtech segment

Neutral: Alkem Laboratories Ltd.

Target

Motilal Oswal

Alkem Lab (ALKEM) is advancing its MedTech strategy through the acquisition of up to a 55% stake in Occlutech for ~EUR99m (~INR10.6b), gaining control of a specialist in minimally invasive devices for congenital heart disease, stroke prevention, and heart failure.

Alkem Laboratories Ltd. is trading below all available SMAs

Alkem Laboratories Ltd.

15 Feb 2026, 12:00AM

5166.00

-0.67%

Alkem Labs (HOLD): Ex - US international segment performing strongly

Hold: Alkem Laboratories Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/APAT reported 1.3%/2.4% and -3.4% below our estimates. EBITDA margin reported 25bps lower than estimates at 22.2%

Alkem Laboratories L.. has an average target of 5736.67 from 3 brokers.

Alkem Laboratories Ltd.

15 Feb 2026, 12:00AM

5166.00

-0.67%

Temporary pause in India; new venture scale-up on cards

Buy: Alkem Laboratories Ltd.

Target

ICICI Securities Limited

Alkem Laboratories (Alkem) reported decent numbers in Q3FY26 led by its international operations. Domestic biz growth slowed to 5.6% YoY, hit by inventory stocking last year and deceleration in trade generics. Management is confident of posting double-digit growth in FY26 (9MFY26 growth at ~10%).

Alkem Laboratories L.. has an average target of 5736.67 from 3 brokers.

Alkem Laboratories Ltd.

14 Feb 2026, 12:00AM

5166.00

-0.67%

Acquisition of Occlutech to open opportunities in Med-tech segment

Neutral: Alkem Laboratories Ltd.

Target

Motilal Oswal

ALKEM is taking significant steps in its Medtech journey through acquiring Occlutech (develops, manufactures, and commercialized medical devices for congenital heart disease, stroke prevention and heart failure).